Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Start Date
5/21/2021
Completion Date
3/1/2028
Summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Eligibility Criteria
Age Range: 18 years to 75 years
Interventions
Budesonide
Conditions
Locations
Dr. Falk Investigational Site
Scottsdale, Arizona 85259
United States
Dr. Falk Investigational Site
Little Rock, Arkansas 72205
United States
Dr. Falk Investigational Site
La Jolla, California 92037
United States
Dr. Falk Investigational Site
Lomita, California 90717
United States
Dr. Falk Investigational Site
San Diego, California 92193
United States
Dr. Falk Investigational Site
Doral, Florida 83706
United States
Dr. Falk Investigational Site
New Port Richey, Florida 34653
United States
Dr. Falk Investigational Site
Boise, Idaho 83706
United States
Dr. Falk Investigational Site
Houma, Louisiana 70363
United States
Dr. Falk Investigational Site
Marrero, Louisiana 70072
United States
Dr. Falk Investigational Site
Boston, Massachusetts 02111
United States
Wyoming
Ann Arbor, Michigan 48109
United States
Dr. Falk Investigational Site
Plymouth, Michigan 55446
United States
Dr. Falk Investigational Site
Wyoming, Michigan 49519
United States
Dr. Falk Investigational Site
Rochester, Minnesota 55905
United States
Dr. Falk Investigational Site
Freehold, New Jersey 07728
United States
Dr. Falk Investigational Site
Jackson, New Jersey 08527
United States
Dr. Falk Investigational Site
New York, New York 10075
United States
Dr. Falk Investigational Site
Chapel Hill, North Carolina 27599-7080
United States
Dr. Falk Investigational Site
Cleveland, Ohio 44195
United States
Dr. Falk Investigational Site
Mentor, Ohio 44060
United States
Wyoming
Philadelphia, Pennsylvania 19104
United States
Dr. Falk Investigational Site
Harlingen, Texas 78550
United States
Dr. Falk Investigational Site
Salt Lake City, Utah 85259
United States
Dr. Falk Investigational Site
Charlottesville, Virginia 22903
United States
Dr. Falk Investigational Site
Lynchburg, Virginia 24502
United States
Department of Gastroenterology, Hospital General de Tomelloso
Tomelloso, 13700
Spain